Prelude Therapeutics
PRLD
47 hedge funds and large institutions have $39.1M invested in Prelude Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 23 reducing their positions, and 8 closing their positions.
78% more capital invested
Capital invested by funds: $22M → $39.1M (+$17.1M)
0.16% less ownership
Funds ownership: 48.15% → 47.99% (-0.16%)
6% less funds holding
Funds holding: 50 → 47 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
65% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$901K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60.4K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$25.9K |
| 4 |
SC
Shay Capital
New York
|
+$25.1K |
| 5 |
HF
HRT Financial
New York
|
+$16.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$171K |
| 2 |
BlackRock
New York
|
-$168K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$100K |
| 4 |
Goldman Sachs
New York
|
-$70K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$65.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$32.4K | -39,977 | Closed |
|
52
Citadel Advisors
Miami,
Florida
| – | -$27.2K | -33,625 | Closed |
|
53
Wells Fargo
San Francisco,
California
| – | -$240 | -297 | Closed |
|
|
TWD
54
True Wealth Design
Akron,
Ohio
| – | -$11 | -13 | Closed |
|
55
Simplex Trading
Chicago,
Illinois
| – | +$153 | +153 | New |
|
PRLD Hedge Fund Activity: Q3 2025 in Review
47 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2025, worth a combined $39.1M — up 78% from $22M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PRLD and 5 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, adding an estimated $901K. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $171K sold.
- 47 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2025, down from 50 in Q2 2025.
- Funds reported $39.1M of Prelude Therapeutics stock for Q3 2025, up 78% quarter-over-quarter.
- 5 funds opened new Prelude Therapeutics positions in Q3 2025 and 8 closed out, a net change of -3 holders.
- The largest Prelude Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $901K added.
- The largest Prelude Therapeutics seller in Q3 2025 was Cantor Fitzgerald, an estimated $171K sold.
Based on aggregated 13F filings for Q3 2025.